| CAT # | Inoa Huahana | wehewehe |
| CPD100603 | MDK36122 | ʻO MDK36122, i kapa ʻia ʻo H-PGDS Inhibitor I, he Prostaglandin D Synthase (hematopoietic-type) Inhibitor. ʻAʻohe inoa code MDK36122, a he CAS #1033836-12-2. Ua hoʻohana ʻia ka helu 5 hope loa no ka inoa no ke kamaʻilio maʻalahi. MDK36122 koho i ka HPGDS (IC50s = 0.7 a me 32 nM i ka enzyme a me ka cellular assays, i kēlā me kēia) me ka hana liʻiliʻi e kūʻē i nā enzymes kanaka pili L-PGDS, mPGES, COX-1, COX-2, a me 5-LOX. |
| CPD100602 | Tepoxalin | ʻO Tepoxalin, i kapa ʻia ʻo ORF-20485; RWJ-20485; he 5-lipoxygenase inhibitor hiki ke mālama i ka hānō, osteoarthritis (OA). Loaʻa i ka Tepoxalin i loko o ka vivo ka hana hoʻoneʻe kūʻē iā COX-1, COX-2, a me 5-LOX i nā ʻīlio ma ke ʻano i ʻae ʻia i kēia manawa. Hoʻonui ʻo Tepoxalin i ka hana o kahi antioxidant, pyrrolidine dithiocarbamate, i ka attenuating tumor necrosis factor alpha-induced apoptosis ma WEHI 164 cell. |
| CPD100601 | Tenidap | ʻO Tenidap, ka mea i kapa ʻia ʻo CP-66248, he mea hoʻopaʻa COX/5-LOX a me ka cytokine-modulating anti-inflammatory moho lāʻau i hoʻomohala ʻia e Pfizer ma ke ʻano he lāʻau lapaʻau kūpono no ka rheumatoid arthritis, akā ua hoʻōki ʻo Pfizer i ka hoʻomohala ʻana ma hope o ka hōʻole ʻia ʻana o ka ʻae kūʻai. e ka FDA i ka makahiki 1996 ma muli o ka make o ka ate a me ka puʻupaʻa, i pili i nā metabolites o ka lāʻau lapaʻau me kahi thiophene moiety. ka mea i poino oxidative. |
| CPD100600 | PF-4191834 | ʻO ka PF-4191834 he puke moʻolelo, ikaika a koho ʻole ʻia ka non-redox 5-lipoxygenase inhibitor kūpono i ka mumū a me ka ʻeha. Hōʻike ʻo PF-4191834 i ka mana maikaʻi i ka enzyme-a me ka cell-based assays, a me ke ʻano hoʻohālike o ka ʻiole o ka ʻeha nui. Hōʻike nā hopena hoʻokolohua Enzyme ʻo PF-4191834 he mea hoʻopale 5-LOX ikaika, me kahi IC(50) = 229 +/- 20 nM. Eia kekahi, ua hōʻike ʻia ma kahi o 300-fold selectivity no 5-LOX ma luna o 12-LOX a me 15-LOX a ʻaʻole hōʻike i kahi hana e pili ana i nā enzyme cyclooxygenase. Eia hou, PF-4191834 kaohi i ka 5-LOX i loko o ke koko koko kanaka, me ka IC(80) = 370 +/- 20 nM. |
| CPD100599 | MK-886 | ʻO MK-886, i ʻike ʻia ʻo L 663536, he mea kūʻē leukotriene. Hiki iā ia ke hana i kēia ma ke kāohi ʻana i ka 5-lipoxygenase activating protein (FLAP), no laila ke kāohi ʻana i ka 5-lipoxygenase (5-LOX), a hiki ke kōkua i ka mālama ʻana i ka atherosclerosis. Kāohi ʻo MK-886 i ka hana cyclooxygenase-1 a hoʻopaʻa i ka platelet aggregation. Hoʻokomo ʻo MK-886 i nā loli i ka pōʻai cell a hoʻonui i ka apoptosis ma hope o ka photodynamic therapy me hypericin. Hoʻonui ka MK-886 i ka ʻokoʻa o ka necrosis factor-alpha-induced apoptosis. |
| CPD100598 | L-691816 | ʻO L 691816 kahi mea hoʻopaneʻe ikaika o ka hopena 5-LO i loko o ka vitro a i loko o kahi ʻano o nā hiʻohiʻona in vivo. |
| CPD100597 | CMI-977 | ʻO CMI-977, ʻike pū ʻia ʻo LPD-977 a me MLN-977, he mea hoʻopaneʻe 5-lipoxygenase ikaika e komo i ka hana ʻana o nā leukotrienes a ke kūkulu ʻia nei no ka mālama ʻana i ka hānō mau loa. Kāohi ʻo CMI-977 i ka 5-lipoxygenase (5-LO) cellular inflammation ala e ālai ai i ka hana o nā leukotrienes, kahi mea nui i ka hoʻoulu ʻana i ka hānō bronchial. |
| CPD100596 | CJ-13610 | ʻO CJ-13610 kahi mea hoʻokae waha o 5-lipoxygenase (5-LO) . Kāohi ʻo CJ-13610 i ka biosynthesis o leukotriene B4 a hoʻoponopono i ka ʻōlelo IL-6 mRNA i nā macrophages. He kūpono ia i nā ʻano preclinical o ka ʻeha. |
| CPD100595 | BRP-7 | ʻO BRP-7 kahi mea hoʻokae 5-LO activating protein (FLAP). |
